Article: Nicotinamide Riboside Prevents Hearing Loss in Cockayne Syndrome: Preclinical Findings

PrevNext
Cardiovascular Disease Cardiovascular Health Preclinical

Nicotinamide Riboside Prevents Hearing Loss in Cockayne Syndrome: Preclinical Findings

Synopsis

Age-related hearing loss (ARHL) is one of the most common disorders affecting elderly individuals. There is an urgent need for effective preventive measures for ARHL because none are currently available. Cockayne syndrome (CS), a premature aging disease, causes early hearing loss similar to age-related hearing loss. Using mouse models of CS, researchers found that NAD+ levels drop in the cochlea. Short-term treatment with nicotinamide riboside (NR), an NAD+ precursor, prevented hearing loss, restored outer hair cells, and improved cochlear health. NR also reversed deficits in synaptic ribbons crucial for hearing, likely by supporting the NAD(H)-dependent protein Ribeye. These results point to NR as a potential treatment for hearing loss in CS and aging.

Journal

npj Aging and Mechanisms of Disease

Share

Read more

Metabolic Health

Nicotinamide Mononucleotide Improves Blood Vessel Function by Converting to Nicotinamide Riboside: Preclinical Findings

Synopsis Nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR) are compounds that help make NAD+, which may protect blood vessels. Researchers studied how NMN and NR affect inflammation...

Read more
Neurological Health

Fixing Imbalanced NAD Metabolism Reduces Effects of Telomere Dysfunction: Preclinical Findings

Synopsis Short telomeres cause diseases like dyskeratosis congenita (DC), which lack effective treatments. This study found that cells from DC patients and telomerase-deficient mice have low NAD+ ...

Read more